News

The Phase IIa randomized, double-blind, placebo-controlled trial evaluated the antiviral activity, pharmacokinetics, safety and tolerability of once- and twice-daily oral dosing regimens of RDEA806 versus placebo in 48

Mr Pascoe succeeds David Hale, who has served as Somaxon’s interim CEO since January 2008. Mr Hale will continue as the company’s executive chairman of the board. Prior

These agreements establish IPC’s operations in two additional northeastern states, expanding its national presence to 18 states. Skip Strauchman, regional executive director of IPC, said: “With our expansion

Medicsight’s ColonCAD computer-aided detection technology aims to assist radiologists in the detection of colorectal neoplasia by automatically highlighting suspicious areas on computed tomography colonography scan images. The software

Juanita Hinshaw, independent member of the board of directors, said: “As a founder of Synergetics and as its CEO, Gregg was instrumental in successfully implementing the company’s growth

Mr Moreadith will lead clinical drug development, clinical pharmacology and toxicology, and regulatory affairs at Nektar. He is responsible for overseeing all aspects of drug development at the

Ore Pharmaceuticals acquired the development rights for romazarit through its partnership with Roche, where it was initially developed as an anti-inflammatory compound and had reached Phase II clinical

The proposal is said to represent a 20% premium above Endocare’s closing stock price on August 6, 2008. James Whittenburg, president and CEO of HealthTronics, said: “After carefully

According to the company, this expands the initial CE Mark approval of the Mirasol pathogen reduction technology (PRT) system for platelets granted in October 2007. The company can